Therefore, it can be used without any hesitation
Regul Pept 41: 149-156, 1992
While our analysis identified significant pharmacovigilance signals, we emphasize these findings represent associations rather than established causation
These observations were supported by our mutagenesis studies, where mutations R299 ECL2 A in GLP-1R, R289 ECL2 A in GIPR and I194 2.67b K in GCGR caused variable decreases in retatrutide potency (by 3.7-fold, 4.6-fold and 36.0-fold, respectively), while S297 ECL2 A in GCGR slightly increased retatrutide potency
Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue, first described by Raun and colleagues in 1998 as the first selective growth hormone secretagogue. It remains one of the most extensively characterised compounds of its class in the published research literature